Skip to main content

Howard Colman, M.D., Ph.D.

Languages spoken: English

Academic Information

Departments: Neurosurgery - Professor, Internal Medicine - Adjunct Professor, Neurology - Adjunct Professor

Divisions: Adult Neurosurgery, Oncology

Academic Office Information

Board Certification

  • American Board of Psychiatry & Neurology (Neurology)
  • United Council for Neurologic Subspecialties (Neuro-oncology)

Research Interests

  • Brain Tumors
  • Clinical Trials
  • Role of Tumors Stem Cells in the Development and Treatment Resistance of Brain Tumors
  • Development and Testing of New Therapies for Brain Tumors
  • Identification of Molecular Markers of Prognosis and Treatment Response in Brain Tumors

Howard Colman, MD, PhD, has multiple clinical interests including the treatment of primary and metastatic brain tumors, and the diagnosis and management of neurologic complications of cancer. His clinical research is focused on the development and testing of new therapies for brain tumors. His laboratory interests include the identification of molecular markers of prognosis and treatment response in brain tumors and the role of tumors stem cells in the development and treatment resistance of brain tumors. He is a Jon M. Huntsman Presidential Professor in the Department of Neurosurgery, a member of the multidisciplinary Brain Tumor Research Team, and is Leader of the Center for Neurologic Cancers at Huntsman Cancer Institute (HCI) at the University of Utah. He is also an HCI investigator and a member of the Experimental Therapeutics program.

Education History

Fellowship University of Texas M.D. Anderson Cancer Center
Chief Resident Washington University School of Medicine
Chief Resident
Residency Barnes-Jewish Hospital, Washington University School of Medicine
Internship Barnes-Jewish Hospital, Washington University School of Medicine
Doctoral Training Washington University School of Medicine
Professional Medical Washington University School of Medicine
Undergraduate Brown University
Neural Sciences

Global Impact


Date Role Description Country
10/01/2015 Member GBM International Adaptive Trial Protocol Writing Committee. China